Phreesia, Inc.

Phreesia, Inc.

PHRNYSE / NASDAQHealthcareSmall cap

$11.41-$0.46 (-3.9%)

Last close · Data as of Nov 20, 2026

Market cap
$599.0M
P/E
259.7x
EV / EBITDA
21.3x
Revenue
$480.6M
Net margin
0.5%
ROCE
-1.4%

-40.1% over the last year

Phreesia, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-5.3%
3M
-4.9%
6M
+28.9%
1Y
-40.1%
5Y
-83.2%

52-week range

Day change -$0.46 (-3.9%) from $12 to $11 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PHR, bought on each weekday since 2021.

News & filings

What Phreesia filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -22.1% to 0.7% between fiscal 2025 and fiscal 2026.

Concerns (1)

  • The P/E of 259.7 is more than four times the peer median of 4.8.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.

Read moreShow less

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.

Sector
Healthcare
Shares outstanding
57.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$599.0M
P/E
259.7x
P/B
1.8x
EV / EBITDA
21.3x
EV / Sales
1.3x
P/S
1.2x
52-week high
$20.62
52-week low
$8.06

Profitability

Operating margin
-1.4%
Net margin
0.5%
EBITDA margin
6.1%
ROE
0.7%
ROCE
-1.4%
ROIC
-0.4%
ROA
0.3%
Asset turnover
0.72

Growth

Revenue
$480.6M
Revenue growth, 1Y
14.5%
Revenue CAGR, 3Y
19.6%
Net profit growth, 1Y
-103.9%
Free cash flow
$54.4M

Solvency

Current ratio
1.53
Debt / Equity
0.30
Debt / Assets
0.15
CFO / Net profit
34.18
Cash / Market cap
12.3%

Where the revenue went

FY2026 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2026
Revenue$480.6M
Cost of revenue$154.1M
Gross profit$326.5M
Operating expenses$333.1M
Research and development$121.5M
Selling, general and administrative$180.2M
Operating income-$6.6M
Interest and other-$2.3M
Pretax income-$8.9M
Tax and other-$11.3M
Net income$2.3M

Revenue and net profit

Revenue grew 14.5% in FY2026; net profit is the dashed line.

Phreesia, Inc. revenue and net profit by fiscal year
Phreesia, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$280.9M-$176.1M
FY2024$356.3M-$136.9M
FY2025$419.8M-$58.5M
FY2026$480.6M$2.3M

Cash flows

FY2026: $78.8M from operations, $54.4M free after investment (dashed).

Phreesia, Inc. operating and free cash flow by fiscal year
Phreesia, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023-$90.1M-$116.3M
FY2024-$32.4M-$57.5M
FY2025$32.4M$8.3M
FY2026$78.8M$54.4M

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$480.6M+14.5%1Y
EBITDA
$29.5M
Net profit
$2.3M
Cash from operations
$78.8M+143.4%1Y
Free cash flow
$54.4M+556.3%1Y
Revenue CAGR, 3Y
19.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$480.6M$29.5M$2.3M$54.4M0.7%+14.5%-103.9%

Monthly returns

Month-by-month returns of PHR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$663.8M
Liabilities$326.6M
Equity$337.2M
Paid-in capital$1.2B
Retained earnings-$799.2M
Treasury stock$45.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PHR highlighted.

P/E against peers

PHR trades at 259.7x earnings against a peer median of 4.8x (a 5256% premium).

Not shown (no positive earnings and no EV / Sales): Prime Medicine, Inc., Beta Bionics, Inc., Ginkgo Bioworks Holdings, Inc., Altimmune, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Phreesia, Inc.PHRthis companyP/E ↑ premium$599.0M259.7x1.8x0.7%21.3x
Prime Medicine, Inc.PRME$626.7M-3.1x5.2x-166.4%-3.4x
Beta Bionics, Inc.BBNX$619.0M-8.5x2.2x-25.5%-8.6x
Gyre Therapeutics, Inc.GYRE$600.6M119.5x5.7x4.7%40.3x
Ginkgo Bioworks Holdings, Inc.DNA$591.2M-1.9x1.2x-61.5%-3.4x
Bioventus Inc.BVS$589.4M25.9x3.2x12.3%8.4x
Altimmune, Inc.ALT$567.9M-6.4x2.5x-39.2%-6.4x
Tactile Systems Technology, Inc.TCMD$567.7M29.7x2.6x8.7%12.4x
MiMedx Group, Inc.MDXG$563.0M11.6x2.2x18.9%5.3x
Peer median—4.8x2.6x-10.4%0.9x

Year-to-date ROI

PHR since 1 January, against earlier years.

Historical volatility

PHR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Phreesia, Inc. operating margin by fiscal year
Phreesia, Inc. operating margin by fiscal year
DateOperating margin
FY2023-62.8%
FY2024-38.3%
FY2025-13.8%
FY2026-1.4%
LineFY2026
Cost of revenueCost Of Revenue$154.1M
Gross profitGross Profit$326.5M
Operating expensesOperating Expense$333.1M
Research and developmentResearch And Development$121.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$31.4M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$31.4M
Depreciation income statementDepreciation Income Statement$13.0M
Amortization$18.5M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$18.5M
Total expensesTotal Expenses$487.2M
Pretax incomePretax Income-$8.9M

Learn while you research

Academy chapters picked for Phreesia, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 259.7, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →